|
1
|
Cammarata-Scalisi F, Girardi K, Strocchio
L, Merli P, Garret-Bernardin A, Galeotti A, Magliarditi F, Inserra
A and Callea M: Oral manifestations and complications in childhood
acute myeloid leukemia. Cancers (Basel). 12(1634)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tomizawa D, Miyamura T, Imamura T,
Watanabe T, Moriya Saito A, Ogawa A, Takahashi Y, Hirayama M, Taki
T, Deguchi T, et al: A risk-stratified therapy for infants with
acute lymphoblastic leukemia: A report from the JPLSG MLL-10 trial.
Blood. 136:1813–1823. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Prada-Arismendy J, Arroyave JC and
Röthlisberger S: Molecular biomarkers in acute myeloid leukemia.
Blood Rev. 31:63–76. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Medinger M, Heim D, Halter JP, Lengerke C
and Passweg JR: Diagnosis and therapy of acute myeloid leukemia.
Ther Umsch. 76:481–486. 2019.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
5
|
Chopra M and Bohlander SK: The cell of
origin and the leukemia stem cell in acute myeloid leukemia. Genes
Chromosomes Cancer. 58:850–858. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Medeiros BC, Chan SM, Daver NG, Jonas BA
and Pollyea DA: Optimizing survival outcomes with post-remission
therapy in acute myeloid leukemia. Am J Hematol. 94:803–811.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tallman MS, Wang ES, Altman JK, Appelbaum
FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M,
et al: Acute myeloid leukemia, version 3.2019, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
17:721–749. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kantarjian H: Acute myeloid leukemia-major
progress over four decades and glimpses into the future. Am J
Hematol. 91:131–145. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ganzel C, Sun Z, Cripe LD, Fernandez HF,
Douer D, Rowe JM, Paietta EM, Ketterling R, O'Connell MJ, Wiernik
PH, et al: Very poor long-term survival in past and more recent
studies for relapsed AML patients: The ECOG-ACRIN experience. Am J
Hematol. 93:1074–1081. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhang L, Sun W, Ren W, Zhang J and Xu G:
Predicting panel of metabolism and immune-related genes for the
prognosis of human ovarian cancer. Front Cell Dev Biol.
9(690542)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Junková K, Mirchi LF, Chylíková B, Janků
M, Šilhavý J, Hüttl M, Marková I, Miklánková D, Včelák J, Malínská
H, et al: Hepatic transcriptome profiling reveals lack of Acsm3
expression in polydactylous rats with high-fat diet-induced
hypertriglyceridemia and visceral fat accumulation. Nutrients.
13(1462)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bi WL, Abedalthagafi M, Horowitz P,
Agarwalla PK, Mei Y, Aizer AA, Brewster R, Dunn GP, Al-Mefty O,
Alexander BM, et al: Genomic landscape of intracranial meningiomas.
J Neurosurg. 125:525–535. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang D, Liu CD, Li HF, Tian ML, Pan JQ,
Shu G, Jiang QY, Yin YL and Zhang L: LSD1 mediates microbial
metabolite butyrate-induced thermogenesis in brown and white
adipose tissue. Metabolism. 102(154011)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yang X, Wu G, Zhang Q, Chen X, Li J, Han
Q, Yang L, Wang C, Huang M, Li Y, et al: ACSM3 suppresses the
pathogenesis of high-grade serous ovarian carcinoma via promoting
AMPK activity. Cell Oncol (Dordr). 45:151–161. 2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gopal R, Selvarasu K, Pandian PP and
Ganesan K: Integrative transcriptome analysis of liver cancer
profiles identifies upstream regulators and clinical significance
of ACSM3 gene expression. Cell Oncol (Dordr). 40:219–233.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yan L, He Z, Li W, Liu N and Gao S: The
Overexpression of Acyl-CoA Medium-Chain Synthetase-3 (ACSM3)
Suppresses the Ovarian Cancer Progression via the Inhibition of
Integrin β1/AKT Signaling Pathway. Front Oncol.
11(644840)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ruan HY, Yang C, Tao XM, He J, Wang T,
Wang H, Wang C, Jin GZ, Jin HJ and Qin WX: Downregulation of ACSM3
promotes metastasis and predicts poor prognosis in hepatocellular
carcinoma. Am J Cancer Res. 7:543–553. 2017.PubMed/NCBI
|
|
18
|
Hu X, Peng WX, Zhou H, Jiang J, Zhou X,
Huang D, Mo YY and Yang L: IGF2BP2 regulates DANCR by serving as an
N6-methyladenosine reader. Cell Death Differ. 27:1782–1794.
2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cui J, Tian J, Wang W, He T, Li X, Gu C,
Wang L, Wu J and Shang A: IGF2BP2 promotes the progression of
colorectal cancer through a YAP-dependent mechanism. Cancer Sci.
112:4087–4099. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Xu X, Yu Y, Zong K, Lv P and Gu Y:
Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic
cancer promotes cancer proliferation by activating the PI3K/Akt
signaling pathway. J Exp Clin Cancer Res. 38(497)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
He X, Li W, Liang X, Zhu X, Zhang L, Huang
Y, Yu T, Li S and Chen Z: IGF2BP2 overexpression indicates poor
survival in patients with acute myelocytic leukemia. Cell Physiol
Biochem. 51:1945–1956. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Swaminathan M and Wang ES: Novel therapies
for AML: A round-up for clinicians. Expert Rev Clin Pharmacol.
13:1389–1400. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhao Z, Zhan Y, Jing L and Zhai H: KLF10
upregulates ACSM3 via the PI3K/Akt signaling pathway to inhibit the
malignant progression of melanoma. Oncol Lett.
23(175)2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shu C, Zheng X, Wuhafu A, Cicka D, Doyle
S, Niu Q, Fan D, Qian K, Ivanov AA, Du Y, et al: Acquisition of
taxane resistance by p53 inactivation in ovarian cancer cells. Acta
Pharmacol Sin. 43:2419–2428. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhu Z, Wang D and Shen Y: Loss of ACSM3
confers worsened prognosis and immune exclusion to cutaneous
melanoma. J Cancer. 11:6582–6590. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
An Y and Duan H: Acyl-CoA medium-chain
synthetase-3 promotes chemosensitivity of ovarian cancer through
the inhibition of PI3K/AKT signaling pathway. Research Square.
2021.
|
|
28
|
Fujii Y, Kishi Y and Gotoh Y: IMP2
regulates differentiation potentials of mouse neocortical neural
precursor cells. Genes Cells. 18:79–89. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Li Z, Gilbert JA, Zhang Y, Zhang M, Qiu Q,
Ramanujan K, Shavlakadze T, Eash JK, Scaramozza A, Goddeeris MM, et
al: An HMGA2-IGF2BP2 axis regulates myoblast proliferation and
myogenesis. Dev Cell. 23:1176–1188. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Boudoukha S, Cuvellier S and Polesskaya A:
Role of the RNA-binding protein IMP-2 in muscle cell motility. Mol
Cell Biol. 30:5710–5725. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Barghash A, Helms V and Kessler SM:
Overexpression of IGF2 mRNA-binding protein 2 (IMP2/p62) as a
feature of basal-like breast cancer correlates with short survival.
Scand J Immunol. 82:142–143. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Barghash A, Golob-Schwarzl N, Helms V,
Haybaeck J and Kessler SM: Elevated expression of the IGF2 mRNA
binding protein 2 (IGF2BP2/IMP2) is linked to short survival and
metastasis in esophageal adenocarcinoma. Oncotarget. 7:49743–49750.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Huang GW, Chen QQ, Ma CC, Xie LH and Gu J:
linc01305 promotes metastasis and proliferation of esophageal
squamous cell carcinoma through interacting with IGF2BP2 and
IGF2BP3 to stabilize HTR3A mRNA. Int J Biochem Cell Biol.
136(106015)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Shen H, Zhu H, Chen Y, Shen Z, Qiu W, Qian
C and Zhang J: ZEB1-induced LINC01559 expedites cell proliferation,
migration and EMT process in gastric cancer through recruiting
IGF2BP2 to stabilize ZEB1 expression. Cell Death Dis.
12(349)2021.PubMed/NCBI View Article : Google Scholar
|
